BioInvent streamlines agreement on anti-FcyRllB antibody, BI-1206, ahead of Phase I/II data LUND, Sweden, Jan. 11, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces it has restructured a clinical development agreement with Cancer Research UK (CRUK), the world's leading cancer charity, for its unique anti-FcyRIIB antibody, BI-1206. In exchange for a one-time payment, the revised deal simplifies and reduces BioInvent's obligations to CRUK, which provides BioInvent with more flexibility to carry out development and partnering activities with BI-1206. It follows BioInvent's exclusive licensing agreement with CASI Pharmaceuticals for the development and commercialization of BI-1206 in mainland China, Taiwan, Hong Kong and Macau.